zepbound glp 1 and gip Dual GIP/GLP-1 Drug Linked to Reduced Diabetic Retinopathy Incidence The Secret Injection Spots To

Pfizer terminated lotiglipron in October 2023 due to dose-dependent liver enzyme elevations, and subsequently discontinued danuglipron in April 2025 after a single case of potential drug-induced liver injury was identified in a dose-optimization study

However, rapid weight loss combined with muscle loss may temporarily destabilize the spine until strength is rebuilt

Conditions like insulin resistance or type 2 diabetes that contribute to weight gain might require ongoing medication support to manage effectively

Results Disclaimer: Individual results will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, adherence to treatment protocols, and other individual variables

Guo J, Hayes MR, Leggio L, Oru E, Rinaman L

Instead, the results suggest that GLP-1 receptor activation may influence brain pathways beyond its effects on weight loss and glucose control